testing the effect of a DPP-4 inhibitor on immune function

在过去的一年里，我们已经获得了临床方案的最终IRB批准，评估dpp -4特异性抑制剂（西格列汀/Januvia）对健康个体免疫功能的影响。1月，协议编号09DK-0055被分配。第一个参与者是在4月份注册的。到2009财年末，共有8名志愿者将被招募，其中3名志愿者将完成研究。另有7人完成了符合纳入/排除标准的调查问卷。这些人将被安排在今年秋天进行筛选访问/潜在注册。研究分析正在进行中。对于迄今为止的所有研究访问，流式细胞术检测已在pbmc上进行。一旦每位志愿者完成所有6次研究访问，将进行其他免疫检测。

In the past year, we have obtained final IRB approval for this clinical protocol, Assessment of the Effects of A DPP-4-Specific Inhibitor (Sitagliptin/Januvia) On Immune Function In Healthy Individuals. In January, the protocol number, 09DK-0055, was assigned. The first participant was enrolled in April. By the end of FY09, a total of 8 volunteers will have been enrolled, and 3 volunteers will have finished the study. An additional 7 individuals have completed questionnaires that have been reviewed to fit within the study inclusion/ exclusion criteria. These individuals will be scheduled for screening visits/ potential enrollment this fall. The research study assays are ongoing. For all study visits to date, flow cytometry assays have been performed on PBMCs. Other immune assays are being done once each volunteer has completed all 6 study visits.